Abstract
A new dosage form consisting of small activated carbon particles which adsorb Aclacinomycin A, Adriamycin, Mitomycin C or Pepleomycin was prepared in order to deliver larger amounts of anticancer agents to the lymph nodes through the high ability of lymphatics to adsorb particles. Animal experiments showed that: The LD50 values of the new dosage form were higher than those of the dosage in solution. The concentration of agents in lymph nodes was maintained at a higher level in the new dosage form than in solution form. Clinically 33% of lymphnodal metastatic lesions became degenerative or inflammatory after a single administration.
MeSH terms
-
Aclarubicin
-
Adsorption
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / therapeutic use
-
Bleomycin / administration & dosage
-
Bleomycin / therapeutic use
-
Charcoal / therapeutic use*
-
Clinical Trials as Topic
-
Dogs
-
Doxorubicin / administration & dosage
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Lethal Dose 50
-
Lymphatic Metastasis / drug therapy*
-
Male
-
Mice
-
Mitomycin
-
Mitomycins / administration & dosage
-
Mitomycins / therapeutic use
-
Naphthacenes / administration & dosage
-
Naphthacenes / therapeutic use
-
Peplomycin
Substances
-
Antineoplastic Agents
-
Mitomycins
-
Naphthacenes
-
Bleomycin
-
Charcoal
-
Mitomycin
-
Peplomycin
-
Aclarubicin
-
Doxorubicin